Jaguar Health Nets $3M by Terminating Buy-Back, Eyes $20M Milestones
Jaguar Health received a $3 million payment from Future Pak by terminating the five-year buy-back option on its U.S. licensing deal for Mytesi® and Canalevia-CA1, following a $16 million non-dilutive injection and $2 million pending. The agreement also offers up to $20 million in milestones as Jaguar advances crofelemer toward rare-intestinal failure NDAs.
1. Funding and Licensing Update
Jaguar Health’s subsidiary Napo Pharmaceuticals received a $3 million payment from Future Pak after terminating the five-year buy-back option in their January 2026 U.S. licensing agreement for Mytesi® and Canalevia-CA1. The original deal provided a $16 million non-dilutive payment in January and a pending $2 million post-closing.
2. Agreement Milestones and Future Payments
Under the agreement, Jaguar maintains manufacturing rights for both crofelemer drugs and can earn up to $20 million in regulatory and commercial milestones. The structure preserves non-dilutive capital while aligning incentives for long-term collaboration and product development.
3. Strategic Focus on Rare-Intestinal Failure
Jaguar is concentrating crofelemer development on rare human intestinal failure indications, including SBS-IF and MVID. Multiple studies across the U.S., EU and UAE are in progress, and the company targets Breakthrough Therapy designation and an MVID NDA filing in H1 2027.
4. Ongoing Commercial and Manufacturing Roles
Future Pak holds exclusive U.S. marketing rights for Mytesi in HIV/AIDS-related diarrhea and Canalevia-CA1 in canine chemotherapy-induced diarrhea, while Jaguar continues to manufacture both products, ensuring supply continuity.